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Abstract
Objectives To evaluate the use of granulocyte colony-stimulating factor (G-CSF) prophylaxis in US patients with selected
metastatic cancers and chemotherapy-induced febrile neutropenia (FN) incidence and associated outcomes among the subgroup
who did not receive prophylaxis.
Methods This retrospective cohort study was conducted at four US health systems and included adults with metastatic
cancer (breast, colorectal, lung, non-Hodgkin lymphoma [NHL]) who received myelosuppressive chemotherapy (2009–
2017). Patients were stratified by FN risk level based on risk factors and chemotherapy (low/unclassified risk, intermediate
risk without any risk factors, intermediate risk with ≥ 1 risk factor [IR + 1], high risk [HR]). G-CSF use was evaluated
among all patients stratified by FN risk, and FN/FN-related outcomes were evaluated among patients who did not receive
first-cycle G-CSF prophylaxis.
Results Among 1457 metastatic cancer patients, 20.5% and 28.1% were classified as HR and IR + 1, respectively. Firstcycle G-CSF prophylaxis use was 48.5% among HR patients and 13.9% among IR + 1 patients. In the subgroup not
receiving first-cycle G-CSF prophylaxis, FN incidence in cycle 1 was 7.8% for HR patients and 4.8% for IR + 1 patients;
during the course, corresponding values were 16.9% and 15.9%. Most (> 90%) FN episodes required hospitalization, and
mortality risk ranged from 7.1 to 26.9% across subgroups.
Conclusion In this retrospective study, the majority of metastatic cancer chemotherapy patients for whom G-CSF prophylaxis is
recommended did not receive it; FN incidence in this subgroup was notably high. Patients with elevated FN risk should be
carefully identified and managed to ensure appropriate use of supportive care.
Keywords Granulocyte colony-stimulating factor . Febrile neutropenia . Breast cancer . Colorectal cancer . Lung cancer .
Non-Hodgkin lymphoma

Introduction
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s00520-020-05715-3) contains supplementary
material, which is available to authorized users.
* Derek Weycker
dweycker@pai2.com
1

Policy Analysis Inc. (PAI), Four Davis Court, Brookline, MA 02445,
USA

2

Henry Ford Health System, Detroit, MI, USA

3

Kaiser Permanente Northwest, Portland, OR, USA

4

Reliant Medical Group, Worcester, MA, USA

5

Amgen Inc., Thousand Oaks, CA, USA

6

Fred Hutchinson Cancer Research Center, Seattle, WA, USA

A common challenge in the treatment of nonmyeloid neoplastic disease is the development of chemotherapyinduced neutropenia [1–5], a condition in which the absolute neutrophil count (ANC) drops below normal (< 0.5 ×
109/L or < 1.0 × 109/L with a predicted decrease to <0.5 ×
10 9 /L) after myelosuppressive chemotherapy [4–7].
Neutropenia is a potentially serious adverse effect that increases the risk of infection and, if untreated, can progress
to febrile neutropenia (FN; fever of ≥ 38.3 °C [101 °F]) [6,
7]. FN can lead to chemotherapy dose schedule alterations,
increased risk of hospitalization, increased healthcare
costs, worse clinical outcomes, and life-threatening complications [1–3, 8, 9].
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The risk of developing FN depends on the myelotoxicity of
chemotherapy regimens as well as patient and disease characteristics [6, 10]. Therefore, according to National
Comprehensive Cancer Network (NCCN) guidelines, prophylactic granulocyte colony-stimulating factor (G-CSF) is recommended for patients undergoing myelosuppressive chemotherapy with a high risk for FN (> 20%) and should be considered in patients with an intermediate risk for FN (10–20%;
with ≥ 1 FN risk factor) to reduce the incidence of FN and
infection-related complications [6, 11]. G-CSFs increase the
production (i.e., differentiation and proliferation) and activity
of neutrophils, which improve immune defense against infection and reduce the risk of FN [12–14]. Despite available
evidence that prophylactic G-CSF is associated with a lower
risk of FN, sustained chemotherapy dose intensity, and reduced mortality [15], several studies have reported that many
patients for whom prophylaxis is recommended do not receive
it in US clinical practice [15–18].
Failure to administer G-CSF prophylaxis could be especially detrimental in patients with metastatic cancer, who are often
older and have more complex comorbidity profiles (vs. nonmetastatic patients) and thus for whom the risk of FN may be
elevated and the consequences of FN may be more severe
[19–21]. The use of intense myelosuppressive chemotherapy
with curative intent has become increasingly common in patients with metastatic solid tumors and advanced NHL.
Accordingly, updated evidence on the use of G-CSF prophylaxis among metastatic cancer patients for whom it is recommended, and the implications among such patients not receiving prophylaxis, are needed. Therefore, this study was undertaken to benchmark the use of G-CSF prophylaxis and the risk
of chemotherapy-induced FN in the absence of G-CSF prophylaxis among patients with metastatic breast cancer, colorectal cancer, lung cancer, and non-Hodgkin lymphoma
(NHL) in US clinical practice.

Methods

planned and administered chemotherapy (i.e., dose,
route, and dates of administration for oral and injectable
drugs), use of supportive care (G-CSFs and antimicrobials), FN risk factors (e.g., demographic characteristics,
labs, comorbid and pre-existing conditions, measures of
health status, treatment history), and study outcomes
(e.g., FN, mortality). A master analytic file including
data from all four study sites was created and used for
analyses described herein. The study was approved by
the institutional review boards of all four participating
health systems.

Source and study populations
The source population included all adults who received
one or more courses of myelosuppressive chemotherapy
for primary breast cancer, colorectal cancer, lung cancer,
or NHL from 2009 to 2017 within the four US health systems. From the source population, patients with evidence
of metastatic disease were selected for inclusion in the
study population. The presence of metastatic disease was
identified based on evidence in cancer registries and/or
electronic medical records; for patients without definitive
information in these two sources, the presence of metastatic disease was determined/confirmed from patient charts.
Patients were excluded from the source/study populations
if they had > 1 invasive primary cancer (excluding
nonmelanoma skin cancer, the same cancer at multiple
sites [e.g., bilateral breast cancer], or an invasive cancer
of interest and an in situ cancer) before initiation of the
first qualifying chemotherapy course or if they had NHL
subtypes other than B cell lymphoma. Patients were also
excluded if information on the use of healthcare services
during the 6-month period before the first qualifying chemotherapy course was incomplete, if their first qualifying
chemotherapy course began before the study period, or if
they initiated chemotherapy while hospitalized.

Study design and data source
Myelosuppressive chemotherapy
This study employed a retrospective observational cohort design and was conducted at four US health systems: Geisinger
Health System, Henry Ford Health System, Kaiser
Permanente Northwest, and Reliant Medical Group
(Supplemental Material). From each health system, requisite
data spanning 2009 to 2017 were collected from data stores
(i.e., administrative databases, electronic medical record systems, cancer registries), as available, and patient medical
charts, as needed, using a standardized case report form
(CRF; Supplemental Material).
Data collected via the CRF included disease characteristics (e.g., cancer type, cancer stage, diagnosis date),

For each patient in the study population, each unique cycle within the first observed full course of myelosuppressive chemotherapy (i.e., the “index course”) was characterized (Supplementary Fig. S1). Chemotherapy regimens
were characterized by planned and actual agents, doses,
and administration schedule (i.e., weekly [QW], every
2 weeks [Q2W], every 3 weeks [Q3W], every 4 weeks
[Q4W]). Chemotherapy regimens were also characterized
according to FN risk level (i.e., high, intermediate, low,
and unclassified) based on the NCCN guidelines [11] and
expert opinion.
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G-CSF prophylaxis
G-CSF prophylaxis was characterized by chemotherapy cycle
and was defined as use of filgrastim or pegfilgrastim (including biosimilars) from the first day of chemotherapy administration in a given cycle through the fifth day after completion
of chemotherapy administration in that cycle. G-CSF prophylaxis was characterized by agent received, dose, route of administration, timing of administration (pegfilgrastim), and duration of administration (filgrastim). Primary prophylaxis was
defined as use beginning in the first cycle, whereas secondary
prophylaxis was classified as reactive G-CSF use (i.e., first
use during the second cycle or later).

others (intermediate risk with no risk factors, low/unclassified
risk). Incidence proportions for FN episodes during cycle 1
and the chemotherapy course were calculated for patients who
did not receive G-CSF prophylaxis in cycle 1 (all cancers and
cancer-specific subgroups, stratified by FN risk level).
Outcomes among patients experiencing FN requiring inpatient care were similarly summarized using percentages and
means, as appropriate. All analyses were conducted using
SAS 9.4 for Windows.

Results
Patients

Febrile neutropenia
FN episodes were ascertained on a cycle-specific basis beginning 6 days after chemotherapy initiation through the last
day of the cycle. FN was defined as having an ANC < 1.0 ×
109/L and, within 1 day, evidence of infection (body temperature ≥ 38.3 °C [101 °F], infection diagnosis, administration
of antimicrobials); neutropenia, fever, or infection diagnosis
in the inpatient setting; or neutropenia, fever, or infection
diagnosis and, on the same date, evidence of antimicrobial
therapy in the outpatient setting. FN-related outcomes were
ascertained among patients requiring inpatient care and included hospital length of stay (LOS) and mortality (which
was ascertained during the cycle in which the episode
occurred).

FN risk factors
Risk factors for FN included age ≥ 65 years, history of chemotherapy or radiation therapy, history of neutropenia, cancer
metastasis to bone, recent surgery, liver dysfunction (i.e., bilirubin > 2.0 mg/dL), and renal dysfunction (i.e., creatinine
clearance < 50 mL/min) [11]. Age was determined at initiation
of the index chemotherapy course; history of chemotherapy
and radiation therapy, any time prior to the course; history of
neutropenia, during the 90-day period before the course; and
recent surgery, during the 60-day period before the course.
Lab values were based on most proximate measurements during the 180-day period before the chemotherapy course.

Statistical analyses
Patient FN risk factors and chemotherapy FN risk levels were
summarized for all patients in the study population, on an
overall basis and by cancer type. Use of G-CSF prophylaxis
in cycle 1 and during the chemotherapy course was described
for all patients and cancer-specific subgroups, respectively,
each of which was further stratified by FN risk level: high risk
[HR], intermediate risk plus ≥ 1 risk factor [IR + 1], and all

The source population included 4091 patients with breast cancer (n = 2007), colorectal cancer (n = 697), lung cancer (n =
936), or NHL (n = 451). Among these patients, 1457 (35.6%)
had metastatic disease and were included in the study population: 380 (26.1%) with breast cancer, 360 (24.7%) with colorectal cancer, 626 (43.0%) with lung cancer, and 91 (6.2%)
with NHL. Results for the metastatic subgroup are described
herein.
Most patients (92.0%) with metastatic disease had ≥ 1 FN
risk factor (Table 1). The most common risk factors were renal
dysfunction (all cancers: 56.8%; range: 45.3% [breast cancer]
to 65.9% [NHL]) and prior chemotherapy or radiation therapy
(all cancers: 42.3%; range: 34.2% [colorectal cancer] to 48.4%
[lung cancer]). Approximately one-third of patients were aged
≥ 65 years (all cancers: 29.2%; range: 20.8% [breast cancer] to
40.7% [NHL]). Additional patient characteristics are available
in Supplemental Table S1.
Nearly half of all patients with metastatic cancer (48.6%)
received chemotherapy regimens with a high FN risk level
(20.5%) or received regimens with an intermediate FN risk
level and had ≥ 1 FN risk factor (28.1%). Breast cancer patients were most likely to receive a chemotherapy regimen
with a high FN risk level (45.8%), whereas colorectal patients
received only regimens with an intermediate, low, or unclassified FN risk level. Information on commonly administered
chemotherapy regimens by cancer type is available in
Supplemental Table S2. The frequency of planned chemotherapy regimens and associated FN risk level for patients with
breast cancer, colorectal cancer, lung cancer, and NHL are
shown in Supplemental Tables S3, S4, S5, and S6,
respectively.

Use of G-CSF prophylaxis
Across all risk categories, 19.6% of patients with metastatic
disease were administered prophylactic G-CSF in cycle 1,
including 48.5% of HR patients, 13.9% of IR + 1 patients,
and 11.1% of all other patients (Fig. 1a). Prophylaxis with
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Table 1

FN risk factors and chemotherapy FN risk level among patients with metastatic cancer

FN risk factors, %
Age ≥ 65 years
Prior chemotherapy or radiation therapy
Prior neutropenia
Bone marrow involvement
Recent surgery
Liver dysfunction (bilirubin > 2.0 mg/dL)
Renal dysfunction (CrCl < 50 mL/min)
≥ 1 of the above
Chemotherapy FN risk level, %
High
Intermediate
≥ 1 FN risk factor
0 FN risk factors
Low
Unclassified

All cancers
(N = 1457)

Breast cancer
(n = 380)

Colorectal cancer
(n = 360)

Lung cancer
(n = 626)

NHL
(n = 91)

29.2
42.3
2.7

20.8
39.2
1.8

21.1
34.2
2.2

37.2
48.4
2.6

40.7
45.1
9.9

22.2
29.0
0.8
56.8
92.0

27.1
40.0
0.8
45.3
86.3

2.8
42.2
1.4
62.2
92.5

30.0
16.9
0.5
59.3
95.0

24.2
14.3
0
65.9
92.3

20.5

45.8

0

17.4

17.6

28.1
2.7
25.6
23.1

10.0
0.5
8.9
34.7

48.9
5.8
22.5
22.8

24.8
1.6
41.2
15.0

44.0
6.6
0
31.9

CrCl, creatinine clearance; FN, febrile neutropenia; NHL, non-Hodgkin lymphoma

G-CSF in cycle 1 ranged from 1.8% (lung cancer) to 80.5%
(breast cancer) among HR patients, 14.8% (lung cancer) to
55.0% (NHL) among IR + 1 patients, and 2.7% (colorectal
cancer) to 20.2% (breast cancer) among all others. During
the chemotherapy course, 57.5% of HR patients, 26.2% of
IR + 1 patients, and 20.3% of all other patients received GCSF prophylaxis in ≥ 1 cycle (Fig. 1b). Course-level use of
prophylaxis by cancer type was similar to prophylaxis use in
cycle 1. Detailed information on prophylaxis with G-CSF is
available in Supplemental Table S7.

Patients with no G-CSF prophylaxis: FN incidence and
outcomes
Among HR patients who did not receive G-CSF prophylaxis
in cycle 1 (n = 154/299; 51.5%), FN incidence was 7.8%
(range: 7.5% [lung cancer] to 8.8% [breast cancer]) during
cycle 1 and 16.9% (range: 7.7% [NHL] to 20.6% [breast cancer]) during the course (Fig. 2a–b). Among IR + 1 patients
who did not receive G-CSF prophylaxis in cycle 1 (n = 352/
409; 86.1%), incidence of FN was 4.8% (range: 0% [breast
cancer] to 11.1% [NHL]) during cycle 1 and 15.9% (range:
10.3% [breast cancer] to 18.2% [lung cancer]) during the
course. Among all other patients who did not receive G-CSF
prophylaxis in cycle 1 (n = 666/749; 88.9%), FN incidence
was 5.3% (range: 3.4% [colorectal cancer and NHL, each] to
7.5% [breast cancer]) during cycle 1 and 14.3% (range: 12.3%
[colorectal cancer] to 24.1% [NHL]) during the course.
Nearly all FN episodes required hospitalization, ranging
from 89.3% among IR + 1 patients to 96.2% among HR

patients. Mean (SD) hospital LOS ranged from 5.1 (2.8) to
6.7 (5.5) days across subgroups defined on FN risk level, and
7.1 to 26.9% of patients who were hospitalized for FN died
during the cycle (Supplemental Table S8).

Discussion
Therapeutic advances in cancer care during the past several
decades have dramatically changed treatment patterns among
cancer patients, especially among those with metastatic disease. Palliative care, with correspondingly low rates of survival, has been increasingly replaced with curative treatment,
often consisting of multiple lines of therapy [22–24].
Although survival rates have improved, the use of more aggressive myelosuppressive regimens carries considerable
risks, including chemotherapy-induced FN, highlighting the
increasing importance of G-CSF prophylaxis among patients
in this population for whom its use is recommended.
In this retrospective analysis of patients receiving myelosuppressive chemotherapy for metastatic cancer at four US
health systems, use of G-CSF prophylaxis varied considerably based on chemotherapy regimen FN risk and presence
of patient risk factors for FN, ranging from 13.8% to 48.5%
in cycle 1 and 26.2% to 57.5% during the course for IR + 1
and HR patients, respectively. Use of G-CSF prophylaxis
varied by cancer type and was greatest among patients with
breast cancer and NHL who, consistent with standard of care
[11, 25, 26], more commonly received chemotherapy regimens with intermediate or high FN risk (breast cancer:
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Fig. 1 Prophylaxis with G-CSF
in all patients with metastatic
cancer and patients with
metastatic breast cancer,
colorectal cancer, lung cancer,
and NHL in cycle 1 (a) and during
the treatment coursea (b). FN,
febrile neutropenia; G-CSF,
granulocyte colony-stimulating
factor; IR, intermediate FN risk
level; LR, low FN risk level;
NHL, non-Hodgkin lymphoma;
UR, unclassified FN risk level.
a
Receipt in ≥ 1 cycle during the
treatment course

56.3%; NHL: 68.1%). Previously published studies have
also reported low or inconsistent use of G-CSFs for patients
with and without metastatic disease, even among those for
whom it is recommended [27–29]. For example, a Cancer
Care Outcome Research and Surveillance Consortium
(CanCORS) study of patients who received chemotherapy
for metastatic and non-metastatic lung or colorectal cancers
found that CSF use during the course was low regardless of
FN regimen risk (10.1%, low; 17.9%, intermediate; 17.2%,
high) [27]. In addition, a more recent study found that CSF

prophylaxis was administered to only 16.7%, 21.9%, and
9.5% of patients with metastatic breast, lung, and colorectal
cancers, respectively, even though regimens with an intermediate or high FN risk level were relatively common
among the study population [29]. These findings are also
consistent with other published studies [16, 17].
The present study is, to the best of our knowledge, the first
to report incidence of FN and FN-related outcomes among
patients with metastatic disease stratified by risk level. Our
findings suggest that among metastatic cancer patients for
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Fig. 2 Incidence of FN in patients
who did not receive primary
prophylactic G-CSF in cycle 1 (a)
and during the treatment course
(b) presented by metastatic breast
cancer, colorectal cancer, lung
cancer, and NHL. FN, febrile
neutropenia; IR, intermediate FN
risk level; LR, low FN risk level;
NHL, non-Hodgkin lymphoma;
UR, unclassified FN risk level

whom primary prophylaxis is recommended but not received,
FN risk is high (course: HR = 16.9%, IR + 1 = 15.9%; cycle 1:
HR = 7.8%, IR + 1 = 4.8%) and associated consequences are
severe (> 90% of cases required hospitalization). These results
are consistent with those from a recently published study of
patients with non-metastatic breast, colorectal, lung, or ovarian cancer or NHL receiving chemotherapy regimens with
intermediate/high FN risk (2010–2016), which found that
FN incidence during cycle 1 among those not receiving

primary prophylaxis with CSF ranged from 3.2% to 5.8%
and that over 80% of FN episodes resulted in hospitalization
[30]. Additionally, in the aforementioned study of patients
with metastatic breast, lung, and colorectal cancer, 13.7% to
20.6% of patients experienced FN during the course, and
88.6% to 93.7% of FN episodes required hospitalization
[29]. Taken together, the findings of this study and previous
research suggest that the risk of FN and consequences thereof
are considerable among patients receiving myelosuppressive
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chemotherapy for metastatic cancers who do not receive GCSF prophylaxis.
The current study has several limitations. The first is its
retrospective design; because histories are left-truncated
and because the accuracy of algorithms/variables capturing patient and treatment characteristics is undoubtedly
less than perfect, some patients may have been
misclassified in terms of their clinical profile.
Furthermore, study outcomes (i.e., G-CSF use, FN risk,
and FN-related outcomes) were identified based on all
relevant information using clinically appropriate algorithms; however, to the extent that such data were missing
and/or algorithms were imperfect, patients may be
misclassified and study results may therefore be biased.
In addition, FN was identified using all relevant information available (e.g., ANC, diagnoses); however, to the
extent that data were missing, the incidence of FN may
have been underestimated. The impact of this limitation,
however, is believed to be negligible given the availability of data from a variety of different sources at each
study site. Finally, because the study population was limited to patients with selected metastatic cancers who received chemotherapy at four US health systems, our study
population may not reflect the population of patients treated in clinical practice across the USA; additional research
using data from other large populations is needed to validate the applicability and accuracy of the characterization
of G-CSF use, FN incidence, and FN-related outcomes
reported in this study.
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